

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

**VOLUNTARY ANNOUNCEMENT
APPROVAL FOR FULL-DEPARTMENT SURGICAL APPLICATION
OF TOUMAI REMOTE BY THE NATIONAL MEDICAL PRODUCTS
ADMINISTRATION OF CHINA**

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Group’s self-developed Full-department Application of Toumai® Laparoscopic Surgery Robot for Remote Surgery (“**Toumai Remote**”) has been approved by the National Medical Products Administration of China (the “**NMPA**”), becoming the world’s first laparoscopic surgical robot approved for the full-department application in remote surgery.

IMPACT ON THE COMPANY

Remote surgery technology is one of the areas that the Company has been working on and focusing on for many years. It is the practice of our belief of “make surgery easier, safer and less invasive”. The approval for Toumai Remote by NMPA is a milestone breakthrough in leading the development of technology and applications in the global robotics field. It will open a new chapter in the industrialisation of global remote surgery and mark the official entry of global surgery into the era of remote surgery. At the same time, the approval of Toumai Remote will further enrich and diversify the Group’s product portfolio. The Toumai series of robots have achieved multi-port, single-port and remote integrated compatibility and can provide hospitals and surgeons with complete and intelligent solutions for laparoscopic surgical robot systems, which will help enhance the competitiveness of the Group’s robot product portfolio in the global market.

ABOUT TOUMAI REMOTE

Toumai Remote is a remote surgery system application for the Company's core product, Toumai Laparoscopic Surgical Robot. It is a world first-in-class technology that is compatible with multiple communication networks, and it has technical advantages in low-latency master-slave control, high-bandwidth network communication and high-stability system architecture design. The Group is the first in the industry to propose the technical concept of "second-generation remote surgery", which is a multi-network integration technology compatible with 5G and conventional hospital networks without reliance on dedicated network cables or specific network suppliers, to achieve one-to-multiple and multiple-to-multiple remote interconnection and control at low cost and continue to lead the global remote surgery innovation and clinical application.

Since its performance of the world's first 5G ultra-remote surgery in June 2022, Toumai Remote has assisted domestic and foreign experts in completing nearly 400 multi-department remote surgeries covering more than 80 hospitals in more than 50 cities in various terrains, marine environments and various climatic conditions in many countries in Asia, America, and Africa, using various communication technologies such as 5G dedicated cables, 5G networks, broadband networks and geosynchronous orbit satellites. The cumulative communication distance has reached nearly 800,000 kilometers, with a 100% implementation success rate, creating more than 40 national and even world records.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in shares of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Mr. Sun Hongbin
Chairman

Shanghai, China, 23 April 2025

As at the date of this announcement, the executive Directors are Dr. He Chao and Ms. Fang Cong, the non-executive Directors are Mr. Sun Hongbin, Mr. Chen Xinxing and Mr. Chen Chen, and the independent non-executive Directors are Dr. Li Minghua, Mr. Yao Haisong and Mr. Chung Wai Man.